DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
|rareLife solutions 606 Post Road East #397
Westport, CT 06880
|You are receiving this because you have an account on www.oneAMYLOIDOSISvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
In February last year, Doherty — now about age 65 — began to experience the same early breathing symptoms his father had had. As an avid hiker who has trekked the Himalayas, he was surprised to find himself getting winded on local hill walks. Testing confirmed that Doherty had a hereditary form of ATTR amyloidosis.
But there was one bit of good news: If Doherty had been diagnosed even a year earlier, no treatment options would have been available to him — an all-too-common situation for over 30 million U.S. patients with rare diseases. But Gillmore, Doherty’s doctor, offered him the chance to participate in an early stage clinical trial using CRISPR, a groundbreaking genome editing therapy with the potential to cure his ATTR amyloidosis in a single dose.
videos & visualsChen (Brazil) – Living With hATTR Amyloidosishttps://www.youtube.com/watch?v=IFlsseEa...
educationHereditary Transthyretin-Related AmyloidosisHereditary transthyretin(TTR)-related am...
educationSenile Systemic Amyloidosis: Clinical Features at Presentation and OutcomeBACKGROUND: Cardiac amyloidosis is a fa...
educationTherapeutic Oligonucleotides Targeting Liver Disease: TTR AmyloidosisThe liver has become an increasingly int...
news & meetingsImplanting Pacemaker Before Liver Transplant Does Not Lead to Better Outcomes, Study RevealsAlthough most patients with familial amy...
videos & visualsAlnylam Clinical Trial Update – ASG Webinar 4/11https://www.youtube.com/watch?v=K2TmwAfu...
people & placesHereditary Amyloidosis CanadaThe Hereditary Amyloidosis Canada (HAC) ...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.